GÖRG advises Merck KGaA on the sale of a research facility to Nuvisan Pharma Grafing GmbH

22.07.2016

[Frankfurt am Main, ] GÖRG advised the leading healthcare and life sciences business Merck KGaA (Darmstadt) on its sale of a pre-clinical research facility in Grafing near Munich to Nuvisan Pharma Grafing GmbH, a business of the Nuvisan group. The undertaking sold is a specialised facility in the area of drug metabolism and pharmacokinetics. In total, about 40 staff members are employed by the facility. The transaction was structured as a sale of assets.

The facility undertakes highly-specialised research and testing of drugs at the pre-clinical stage. Merck KGaA has ensured that the expertise of the facility will remain available to it in future by entering into a long-term partnership.

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.

The GÖRG team advising on the sale consisted of experts in the areas of corporate/M&A, healthcare and regulatory law, labour law and real estate law.

Merck KGaA

Rose Brounts, in-house counsel, Group Legal & Compliance

Advisors to Merck KGaA

GÖRG Partnerschaft von Rechtsanwälten mbB
Dr. Michael Heise LL.M. (University of Pennsylvania), Associated Partner, Corporate/M&A, Frankfurt am Main (transaction lead)
Dr. Lars Nevian, Partner, Labour, Frankfurt am Main
Christopher J. Wright, J.D., LL.M., Counsel, Corporate/M&A, Berlin
Dr. Ulrich Jacob, Counsel, Real Estate, Frankfurt am Main
Dr. Marc Schüffner, Associated Partner, Healthcare/Regulatory, Berlin
Dr. Heiko Reiter, Associate, Labour, Frankfurt am Main

Advisors to Nuvisan Pharma Grafing GmbH

TRACC Legal Rechtsanwälte GbR (Munich)
Dr. Thomas Lotz, Corporate/M&A, Munich
Dr. Thorsten Steinhaus, Corporate/M&A, Munich

 Newsletter Icon

We inform you about current legal developments in the areas relevant to you.

Subscribe to our Newsletter

Anmedlung Newsletter

Einige der von uns gesetzten Cookies dienen dazu, bestimmte Funktionen unserer Webseiten zu ermöglichen, insbesondere zur Steuerung des Cookie-Banners (damit dieses bei Ihren erneuten Besuchen nicht immer wieder angezeigt wird). Diese Cookies enthalten keine personenbezogenen Daten, insbesondere nicht Ihre IP-Adresse. Andere Cookies, die zu Analysezwecken gesetzt werden (siehe hierzu auch den Abschnitt „Web-Analyse-Tools“), helfen uns zu verstehen, wie Besucher mit unseren Webseiten interagieren. Diese Cookies dienen dazu, die Nutzung unserer Webseiten statistisch zu erfassen und zum Zwecke der Optimierung unseres Angebotes auszuwerten. Die Analyse-Cookies werden bis zu 13 Monate gespeichert.

Save Cancel OK Tracking ablehnen Datenschutzerklärung